<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452228</url>
  </required_header>
  <id_info>
    <org_study_id>R1500-HTG-1522</org_study_id>
    <secondary_id>2016-003307-62</secondary_id>
    <nct_id>NCT03452228</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the change in Triglyceride (TG) levels following 12
      weeks of repeated Intravenous (IV) doses of evinacumab.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Anticipated">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent lowering of TG levels from baseline following 12 weeks of repeated IV doses of evinacumab</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent TG lowering from baseline following 2 to 24 weeks of repeated IV doses of evinacumab</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient reported abdominal and GI daily symptom questionnaire</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in patient reported daily dietary habits and impact questionnaire</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of pancreatic injury/inflammation through 18F-2-Fluoro-2-Deoxy-D glucose positron emission tomography (18F-FDG-PET) imaging at baseline as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to degree of pancreatic injury/inflammation through 18F-FDG-PET imaging following 12 weeks of treatment with evinacumab as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of pancreatic injury/inflammation through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) at baseline as assessed by ADC</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab as assessed by ADC</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab as assessed by ADC</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total evinacumab concentration in serum</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ANGPTL3 concentrations</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Severe Hypertriglyceridemia (sHTG)</condition>
  <arm_group>
    <arm_group_label>evinacumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evinacumab</intervention_name>
    <description>Administered by Intravenous (IV)</description>
    <arm_group_label>evinacumab</arm_group_label>
    <other_name>REGN1500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by Intravenous (IV)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Previous documentation in the patient's medical records of a fasting serum TG
             measurement ≥ 1000 mg/dL (11.3 mmol/L) on more than 1 occasion, and all fasting TG
             values ≥500 mg/dL (5.6 mmol/L) at screening

          2. History of a hospitalization and diagnosis of acute pancreatitis in the past 10 years

          3. On stable lipid-modifying diet with or without medications (eg, statins, niacin,
             omega-3 fatty acids). Lipid-modifying diet and doses of medications should be stable
             for at least 4 weeks (6 weeks for fibrates, 8 weeks for PCSK9 inhibitors) prior to
             screening

          4. Body mass index (BMI) of 18-40 kg/m2

        Key Exclusion Criteria:

          1. A hospital or clinic discharge diagnosis of acute pancreatitis within 12 weeks of
             screening

          2. Lipid apheresis or plasma exchange treatment within the last 4 weeks or plans to
             undergo apheresis or plasma exchange during the time frame of the study

          3. History of class 3/4 heart failure at any time in the past, or hospitalization for
             heart failure, diagnosis of a myocardial infarction, stroke, Transient ischemic attack
             (TIA), unstable angina, Coronary artery bypass surgery (CABG), Percutaneous coronary
             intervention (PCI), carotid surgery/stenting within 3 months before the screening
             visit

          4. History of bleeding disorders, esophageal varices, heparin induced thrombocytopenia,
             or contraindications to receiving heparin (eg, allergic reaction to heparin)

          5. Previous treatment with Glybera® in the past 5 years or treatment with lomitapide or
             mipomersen in the past 6 months

          6. Pregnant or breast feeding women

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

